Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, Palvella Therapeutics, Inc. reported revenue of $43M, up 65.3% year over year. Operating margin was -27.7% and net margin 43.7%, on a free-cash-flow margin of -32.4% with capital expenditure at 0.4% of revenue. Every figure is computed directly from PVLA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $43M | -27.7% | 43.7% |
| FY2022 | $26M | -167.8% | -128.5% |
| FY2021 | $31M | -165.0% | -145.6% |
| FY2020 | $29M | -115.7% | -127.0% |
How does PVLA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.